Cupid Ltd. shares rose 7.05% to an intraday high of ₹276.25 following the company's announcement of upgraded FY27 profit and revenue outlook at its 33rd Annual General Meeting. According to reports from The Economic Times, the consumer wellness and personal care company cited strong growth in both global healthcare and Bharat consumer business segments as the driver behind the positive guidance revision. The stock has delivered exceptional returns, gaining 160% in 2026 and 520% over the past year, significantly outperforming broader market indices.
The company delivered exceptional FY26 results, with total income increasing 93% to ₹391 crore from ₹203 crore, while profit after tax grew 165% to ₹108 crore from ₹41 crore. As reported by The Economic Times, the company exceeded its initial FY26 guidance of ₹335 crore revenue and ₹100 crore profit, ending the year with its strongest quarter in history. EBITDA increased 180% and net profit margin crossed 30%, with net worth rising from ₹342 crore to ₹451 crore. The robust quarterly performance, combined with a strong order pipeline and momentum across both business engines, supported the company's decision to raise its FY27 guidance.
Cupid raised its FY27 guidance to revenue of ₹725–750 crore and net profit of ₹210–225 crore, according to the exchange filing reported by The Economic Times. For the medium term, the company is targeting revenue of ₹1,085 crore in FY28 and ₹1,500 crore in FY29. The growth strategy is supported by a wider distribution network across Bharat, increasing contributions from consumer products, new manufacturing capacity, global tender opportunities and an expanding international healthcare platform. Commenting on the development, Chairman & Managing Director Aditya Kumar Halwasiya highlighted the company's progress in strengthening its core business and building new capabilities.
The company's global business serves national health programmes, multilateral agencies and brand owners across international markets, with exports reaching ₹208 crore in FY26, accounting for nearly 60% of revenue across more than 125 countries. As reported by The Economic Times, the consumer business contributed approximately ₹122 crore in FY26, including ₹84 crore from recently launched FMCG products. The company is developing nitrile manufacturing capabilities and has received European IVDR certification for HIV, Hepatitis B, Syphilis and pregnancy test kits. Cupid remains the first company globally to receive WHO/UNFPA pre-qualification for both male and female condoms. The growth strategy increasingly focuses on moving from global leadership to consumer scale, combining established global healthcare business with growth opportunities in Bharat's consumer market.
Cupid is developing significant manufacturing capabilities through its 170,000 sq ft Palava facility scheduled for commissioning in the next quarter, expected to support total capacity of approximately 1.25 billion male condoms and 125 million female condoms annually at full capacity. The company has committed ₹331.53 crore to Baazar Style Retail, providing access to more than 280 stores with potential to cross 500 stores over the next two to three years, contributing approximately ₹150 crore of revenue in FY27. Additionally, Cupid made an additional $5 million follow-on investment in GII Healthcare Investment Limited in July 2026 and received in-principle approval for a proposed manufacturing venture in South Africa with up to 49% stake.
